Robert W. Baird analyst Brian Skorney maintained a Sell rating on Amgen Inc (NASDAQ:AMGN) on Thursday, setting a price target of $185, which is approximately 15.67% below the present share price of $219.38.
Skorney expects Amgen Inc to post earnings per share (EPS) of $0.81 for the third quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in Amgen, with an average price target of $245.
The analysts price targets range from a high of $278 to a low of $185.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $6.53 billion and a net profit of $2.33 billion. The company's market cap is $124.58 billion.
According to TipRanks.com, Robert W. Baird analyst Brian Skorney is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 2.6% and a 49.49% success rate.
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.